While the Managing Cancer and Living Meaningfully (CALM) therapy leads to improvements in depressive symptoms over time, it does not appear to be better than supportive psycho-oncological counselling intervention, a new trial has found.
Treatment with the oral combination of 17β-oestradiol and progesterone in postmenopausal women does not appear to be related to abnormal mammograms, and the incidence of breast tenderness is low as compared with the rates reported in other hormone therapy studies, according to data from the phase III trial REPLENISH.
A small set of multiple myeloma (MM) patients will show exceptional response to autologous stem cell transplantation (ASCT) and remain progression-free for years without maintenance therapy, a recent study has found.
The convolutional neural network (CXR-LC) model has successfully pinpointed smokers who are at increased risk for incident lung cancer beyond Centers for Medicare & Medicaid Services (CMS) eligibility and using information commonly available in the electronic medical record (EMR), reports a study.
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.